Tong Ren Tang Technologies Schedules Board Meeting to Approve 2025 Results and Consider Dividend

The latest announcement is out from Tong Ren Tang Technologies Co ( (HK:1666) ).

Tong Ren Tang Technologies Co. Ltd. has scheduled a board meeting in Beijing on 27 March 2026 to review and approve the audited consolidated results for the year ended 31 December 2025. The board will also consider proposing a final dividend, potential closure of the register of members, and other routine corporate matters, decisions that may affect shareholder entitlements and signal the company’s financial performance and capital allocation stance.

The meeting’s agenda underscores the company’s move into its regular annual results cycle, with the forthcoming publication of audited figures on the Hong Kong Stock Exchange expected to provide investors with clarity on operating trends. Any dividend recommendation and decisions regarding the register of members will be closely watched by shareholders as indicators of profitability, cash flow strength, and management’s confidence in future prospects.

The most recent analyst rating on (HK:1666) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Tong Ren Tang Technologies Co stock, see the HK:1666 Stock Forecast page.

More about Tong Ren Tang Technologies Co

Tong Ren Tang Technologies Co. Ltd. is a Hong Kong-listed joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical and healthcare sector through Tong Ren Tang’s traditional Chinese medicine heritage. The group focuses on the manufacture and sale of Chinese patent medicines and related healthcare products in mainland China and international markets.

YTD Price Performance: -4.76%

Average Trading Volume: 1,155,550

Technical Sentiment Signal: Sell

Current Market Cap: HK$5.38B

For a thorough assessment of 1666 stock, go to TipRanks’ Stock Analysis page.